Testosterone Treatment for Multiple Sclerosis

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-04-30

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Since men are less likely to develop multiple sclerosis, the hypothesis was that testosterone might be protective in MS. Men with MS for followed untreated for 6 months, followed by a 12 month treatment period with Androgel.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Testosterone for Fatigue in Men With MS

NCT03000127

Multiple Sclerosis

WITHDRAWN PHASE2

Testosterone Treatment for Erectile Dysfunction and Multiple Sclerosis

NCT04601233

Multiple Sclerosis Erectile Dysfunction Testosterone Deficiency

NOT_YET_RECRUITING PHASE4

Neuroendocrine Dysfunction in Traumatic Brain Injury: Effects of Testosterone Therapy

NCT01201863

Endocrine Dysfunction Trauma Brain Injury

COMPLETED PHASE4

Testosterone Gel in Preventing Weakness Caused by Steroid Therapy in Men With Glioma

NCT00631137

Brain and Central Nervous System Tumors Musculoskeletal Complications

TERMINATED NA

A Clinical Trial to Evaluate the Efficacy and Safety of Testosterone Gel in Adult Hypogonadal Males

NCT02149264

Adult Male Hypogonadism

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Background: Men are less susceptible to many autoimmune diseases including multiple sclerosis (MS). Possible causes for this include sex hormones and/or sex chromosome effects. Testosterone treatment ameliorates experimental allergic encephalomyelitis (EAE), an animal model of MS, but the effect of testosterone supplementation on men with MS is not known.

Design, Setting and Participants: Ten men with relapsing remitting MS were studied using a crossover design whereby each patient served as his own control. There was a six-month pretreatment period followed by a twelve month period of daily treatment with 100mg of testosterone gel.

Main Outcome Measures: Brain atrophy and Cognitive testing

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Multiple Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

crossover treatment with Androgel

6 months pretreatment, 12 months treatment intervention with Androgel 10 grams of gel containing 100mg of testosterone

Group Type EXPERIMENTAL

Androgel 10 grams of gel containing 100 mg of testosterone

Intervention Type DRUG

testosterone gel

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Androgel 10 grams of gel containing 100 mg of testosterone

testosterone gel

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

testosterone

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Men, age 18-65, with a diagnosis of clinically definite relapsing remitting multiple sclerosis.
2. Relapsing remitting patients who have declined or not tolerated treatment with beta interferon (Betaseron, Avonex) or glatiramer acetate, copolymer-1 (Copaxone).
3. At least one relapse in the two years prior to entry. Relapse will be defined historically as definite worsening of a previous symptom (over 0-3 days) or development of a new symptom (over 0-3 days).
4. Not in an intercurrent relapse.
5. Expanded Disability Status Score (EDSS) = 0.0 to 5.0.
6. The patients must have a significant T2 burden of disease on screening cerebral MRI as defined by T2 lesion loads greater than 7.5cm3.
7. Must live within 100 miles of UCLA.
8. Must be willing and able to receive an initial screening cerebral MRI, a baseline MRI and monthly cerebral MRIs (with and without gadolinium) for a total period of 12 months (6 months prior to treatment and 6 months during treatment).

Exclusion Criteria

1. Males unable to fulfill the above criteria and all female patients.
2. Males who have been on sex hormone treatment including androgens, estrogens, or anti-estrogens for hypogonadism or other medical condition during the 12 months prior to study.
3. Males who have taken DHEA during the 3 months prior to study.
4. Patients who have thrombosis, serious cardiac, pulmonary, renal, gastrointestinal, hepatic, immunologic, infectious, neoplastic (with particular focus on patients with known or suspected estrogen or testosterone-dependent tumors), or urologic disease (with a particular focus on patients with a history of prostatic hypertrophy/nodules).
5. Patients with an abnormal prostate as evidenced by prostatic masses or induration on rectal examination or prostate ultrasonography or elevated levels of prostatic specific antigen (PSA 4 ng/ml or higher).
6. Patients with testicular mass on exam.
7. Patients with hematocrit greater than 50%
8. Patients with major psychiatric illness (e.g. manic depressive states, schizophrenia)
9. Patients with active alcoholism.
10. Patients with a history of drug abuse within the past five years.
11. Patients who are greater than 130% or less than 80% of their ideal body weight based on Metropolitan Life Tables.
12. Patients with generalized skin disease that may effect absorption of testosterone (e.g. psoriasis) or a known skin intolerance to alcohol.
13. Patients with prolactin \> 40 mcg/L.
14. Patients with a cholesterol level greater than 300 mg/dl.
15. Patients with other conditions that would interfere with assessing neurologic functions such as deforming arthritis or a major amputation.
16. Patients who have received treatment with beta interferon (Betaseron or Avonex), glatiramer acetate copolymer-1 (Copaxone), ACTH, corticosteroids, intravenous immunoglobulins (IVIG), or plasma exchange in the three months preceding enrollment
17. Patients who have received treatment with azathioprine, cyclophosphamide, methotrexate, mitoxantrone, cyclosporin A or experimental therapies in the six months preceding enrollment.
18. Patients who have been treated with total lymphoid irradiation, monoclonal antibody, T cell vaccination, cladribine or bone marrow transplantation.
19. Patients who have positive titers to HIV1,2; HTLV1; or VDRL.
20. Patients who have clinical evidence of Lyme disease.
21. Patients who are mentally or emotionally incompetent in the opinion of the examining neurologist or unable to give informed consent, or to understand and comply with the study protocol.
22. Patients with certain artificial heart valves, pacemakers, or other metallic/electronic material in their bodies.
23. Patients with known hypersensitivity to gadolinium-DPTA.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No